• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Canada
  • United Kingdom
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Coronavirus > 5 things to know in life sciences: Week of Feb. 1

5 things to know in life sciences: Week of Feb. 1

Feb. 5, 2021 by Steve Kemler and Adam Lohr

  • email
  • Twitter
  • Facebook
  • Linkedin

In this week’s roundup, we examine why more drug manufacturers are not stepping in to help produce mRNA-based COVID-19 vaccines. While some may think drug manufacturing facilities should be able to easily pivot to produce these vaccines, the reality is much more complicated.

We also look at investment patterns in gene therapy companies, a new Food and Drug Administration role that underscores the importance of cybersecurity for medical devices, and the increased use of patient assistance programs. Finally, we try to separate the hype from the reality of what is possible with the use of artificial intelligence in clinical trials and drug development.

Each week, we highlight five things you need to know about in the life sciences industry. Here’s the latest.

There is not idle mRNA drug manufacturing capacity available for COVID-19 vaccines

With the entire world anxious for vaccine production to ramp up and for doses to become more broadly available, many people are wondering why companies can’t increase production faster. This great blog in Science Translational Medicine (linked above) details the steps involved in manufacturing mRNA vaccines and why drug companies cannot quickly adapt to add capacity.

Gene therapy holds a great deal of promise and is driving investment and M&A

Investments in 2020 in gene therapy stress an important and ongoing trend – major life sciences companies continue to focus on acquiring drug candidates and entire companies in this space as a means of supplementing their internal development pipelines. This article in Endpoints News breaks down the deals in 2020 and looks at the potential impact of recent gene therapy safety issues on future deals.

FDA appoints first medical device cybersecurity chief

As more and more medical devices add connectivity features, the importance of cybersecurity for these devices continues to increase. To address this reality, the FDA has named its first chief of medical device security – Kevin Fu, an associate professor at the University of Michigan. This important role will help ensure that device security is a focus of the agency, while also continuing to support innovation and patient safety.

Amid the pandemic, more people are turning to patient assistance programs

Patient assistance programs have existed for quite some time to help offset the costs of high-priced drugs for patients that otherwise might not be able to afford them. In 2020, with broad economic pain, high unemployment, and increased poverty, PAPs became more critical than ever. As this Pharmaceutical Executive article highlights, the expansion of such programs will require increased awareness and for pharma companies to adjust their qualification criteria and update systems to support their broader use.

Artificial intelligence is moving beyond hype and starting to make an impact in clinical trials

Without closer examination, some people may write off artificial intelligence as an overhyped technology. But for some clinical trials, AI is starting to have a more tangible impact. Clinical Leader recently sat down with several experts in the clinical trial space with the goal of clarifying where AI is making a difference in clinical trials, and where it is not.

(Bonus read: Companies like Cellino, which uses AI to enhance its regenerative medicine pipeline, are drawing investment.)

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • 5 things to know this week in life sciences: Week of Jan. 11

    News this week included Bluebird Bio’s announcement about splitting into two companies, the promise of quantum computing in drug design, and how mRNA platforms offer promise for diseases beyond COVID-19.

  • 5 things to know this week in life sciences: Week of Dec. 14

    With the Food and Drug Administration approving the first COVID-19 vaccine for emergency use last week, the focus around the vaccine will start to shift toward public health messaging and how to convince tens of millions of people…

  • 5 things to know this week in life sciences: Week of Jan. 4

    In this week’s industry roundup, we look at recent drug price increases, the ongoing battle over 340B program discounts, key catalysts in Q1 for middle market biotech companies, and more.

Filed Under: Coronavirus, Life Sciences Tagged With: coronavirus, Covid-19, covid-19 vaccine, Food and Drug Administration, life sciences, vaccine

About Steve Kemler

Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.

As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.

In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

About Adam Lohr

Adam is an audit partner and life sciences senior analyst in RSM's cutting-edge industry eminence program. In addition to providing assurance services to his clients, he sits on RSM’s national life science team and leads the San Diego office life science practice.

His senior analyst responsibilities include advising the firm’s life sciences care clients and client servers as they work to navigate the rapidly changing industry environment. Adam regularly writes, presents and advises on capital markets, digital transformation, policy and other issues transforming life sciences. He is an instructor at the regional and national level, and is experienced in the application of ASC 606 revenue recognition for the technology and consumer products industries.

Adam has over 12 years of accounting and finance experience, serving private equity-backed and private closely held companies in the middle market. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their business.

Primary Sidebar

Other Regions

  • Canada
  • United Kingdom

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Life Science articles

5 things to know in life sciences: Week of March 1

Mar. 4, 2021

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences